Roche shares decline after oral breast cancer drug trial failure

Shares in Roche fell over five percent after clinical trials revealed that its breast cancer drug giredestrant did not demonstrate efficacy in newly diagnosed patients when used in combination with Pfizer’s Ibrance. The late-stage trial failed to show significant disease progression benefits compared to standard hormonal therapy. Roche’s prior success with giredestrant had raised expectations, but analysts now express concerns about its market potential, especially against competitors like AstraZeneca’s camizestrant.

Want More Context? 🔎

Perspective Meter

LeftCenterRight

?

Bias score hidden

Left-Leaning Coverage

Right-Leaning Coverage

AI Summary

Upgrade to Tidal Access to see the bias score